Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

NCT02500784 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding ran out before study started, prior PI left institution.

Conditions

Alzheimer's Disease
Cognitive Dysfunction

Interventions

DRUG: Formoterol A
OTHER: Formoterol B (placebo)

Sponsor

Palo Alto Veterans Institute for Research

Collaborators

[object Object]
[object Object]